Tvardi Therapeutics, Inc. (NasdaqCM: TVRD)
Health Care · Pharmaceuticals · US
$1.82
-4.21% today · -92.3% 1Y
Tvardi Therapeutics, Inc. (NasdaqCM: TVRD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $17.82M and employs 12 people.
Over the last twelve months the share price has lost 92.3%, trading between 1.50 and 43.65.
Tweenvest scores Tvardi Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
TVRD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.82M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.77
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $43.65
- 52-week low
- $1.50
- Avg volume (3M)
- —
- Shares outstanding
- 9.38M
- Employees
- 12
- Next earnings
- —
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
- ISIN
- US1407553072
- Founded
- 2017
- Listed since
- Jan 31, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.